Evidence map›Paper›PMID 34237137›Full record

ArticleBioinformatics (Oxford, England)2021

A novel systematic approach for cancer treatment prognosis and its applications in oropharyngeal cancer with microRNA biomarkers.

Shenghua He, Chunfeng Lian, Wade Thorstad, Hiram Gay, Yujie Zhao, Su Ruan, Xiaowei Wang, Hua Li

Abstract read
In one paragraph

Article in Bioinformatics (Oxford, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Shenghua HeDepartment of Computer Science and Engineering, Washington University in Saint Louis, St. Louis, MO 63130, USA.
Chunfeng LianSchool of Mathematics and Statistics, Xi'an Jiaotong University, Xi'an, 710049 Shaanxi, China.
Wade ThorstadDepartment of Radiation Oncology, Washington University in Saint Louis, St. Louis, MO 63130, USA.
Hiram GayDepartment of Radiation Oncology, Washington University in Saint Louis, St. Louis, MO 63130, USA.
Yujie ZhaoCarle Cancer Center, Carle Foundation Hospital, Urbana, IL 61801, USA.
Su RuanLaboratoire LITIS (EA 4108), Equipe Quantif, University of Rouen, 76183 Rouen, France.
Xiaowei WangDepartment of Radiation Oncology, Washington University in Saint Louis, St. Louis, MO 63130, USA.ORCID 0000-0001-9447-4685
Hua LiCarle Cancer Center, Carle Foundation Hospital, Urbana, IL 61801, USA.ORCID 0000-0002-5629-2247

Funding

MICRORNA BIOMARKERS FOR OROPHARYNGEAL CANCERR01DE026471 · NIDCR · WASHINGTON UNIVERSITY · PI WANG, XIAOWEI · 2017 to 2021
$2.2M
Multimodal Biomarkers For Oropharyngeal CancerR01CA233873 · NCI · WASHINGTON UNIVERSITY · PI LI, HUA · 2019 to 2024
$2.0M
RADIOMICS-BASED PROGNOSTIC MODEL OF CERVICAL CANCER HABITATSR21CA223799 · NCI · WASHINGTON UNIVERSITY · PI GRIGSBY, PERRY WAYNE, LI, HUA · 2018 to 2019
$368k
National Institutes of Health Award R01DE026471NCI NIH HHS R01 CA233873NCI NIH HHS R21 CA223799NIDCR NIH HHS R01 DE026471
6 · The paper itself

Abstract

motivationPredicting early in treatment whether a tumor is likely to respond to treatment is one of the most difficult yet important tasks in providing personalized cancer care. Most oropharyngeal squamous cell carcinoma (OPSCC) patients receive standard cancer therapy. However, the treatment outcomes vary significantly and are difficult to predict. Multiple studies indicate that microRNAs (miRNAs) are promising cancer biomarkers for the prognosis of oropharyngeal cancer. The reliable and efficient use of miRNAs for patient stratification and treatment outcome prognosis is still a very challenging task, mainly due to the relatively high dimensionality of miRNAs compared to the small number of observation sets; the redundancy, irrelevancy and uncertainty in the large amount of miRNAs; and the imbalanced observation patient samples.

resultsIn this study, a new machine learning-based prognosis model was proposed to stratify subsets of OPSCC patients with low and high risks for treatment failure. The model cascaded a two-stage prognostic biomarker selection method and an evidential K-nearest neighbors classifier to address the challenges and improve the accuracy of patient stratification. The model has been evaluated on miRNA expression profiling of 150 oropharyngeal tumors by use of overall survival and disease-specific survival as the end points of disease treatment outcomes, respectively. The proposed method showed superior performance compared to other advanced machine-learning methods in terms of common performance quantification metrics. The proposed prognosis model can be employed as a supporting tool to identify patients who are likely to fail standard therapy and potentially benefit from alternative targeted treatments. Availability and implementation: Code is available in https://github.com/shenghh2015/mRMR-BFT-outcome-prediction.

Identifiers

PMID34237137
PMCPMC12161116

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.